HUP9801834A3 - Liposome formulations of 5beta steroids - Google Patents

Liposome formulations of 5beta steroids

Info

Publication number
HUP9801834A3
HUP9801834A3 HU9801834A HUP9801834A HUP9801834A3 HU P9801834 A3 HUP9801834 A3 HU P9801834A3 HU 9801834 A HU9801834 A HU 9801834A HU P9801834 A HUP9801834 A HU P9801834A HU P9801834 A3 HUP9801834 A3 HU P9801834A3
Authority
HU
Hungary
Prior art keywords
liposome formulations
5beta
steroids
5beta steroids
liposome
Prior art date
Application number
HU9801834A
Other languages
English (en)
Original Assignee
Supergen Inc Emeryville
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Supergen Inc Emeryville filed Critical Supergen Inc Emeryville
Publication of HUP9801834A2 publication Critical patent/HUP9801834A2/hu
Publication of HUP9801834A3 publication Critical patent/HUP9801834A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
HU9801834A 1995-10-12 1996-09-27 Liposome formulations of 5beta steroids HUP9801834A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54208395A 1995-10-12 1995-10-12

Publications (2)

Publication Number Publication Date
HUP9801834A2 HUP9801834A2 (hu) 1999-02-01
HUP9801834A3 true HUP9801834A3 (en) 2000-06-28

Family

ID=24162270

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9801834A HUP9801834A3 (en) 1995-10-12 1996-09-27 Liposome formulations of 5beta steroids

Country Status (10)

Country Link
US (1) US6436435B1 (hu)
EP (1) EP0801557B1 (hu)
JP (1) JPH10508322A (hu)
CN (1) CN1173815A (hu)
AT (1) ATE243998T1 (hu)
CA (1) CA2208215A1 (hu)
DE (1) DE69628909T2 (hu)
HU (1) HUP9801834A3 (hu)
IL (1) IL121070A (hu)
WO (1) WO1997013500A2 (hu)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6667299B1 (en) 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
US20070129282A1 (en) * 1998-11-24 2007-06-07 Ahlem Clarence N Pharmaceutical treatments and compositions
CA2670236C (en) * 1999-09-30 2012-06-05 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment of androgen receptor driven conditions
FR2799645B1 (fr) 1999-10-13 2004-04-30 Oreal Utilisation de la dhea ou de ses precurseurs ou derives metaboliques comme depigmentant
JP2003512474A (ja) * 1999-10-25 2003-04-02 ホリス − イーデン ファーマスーティカルズ、 インコーポレイテッド 血液細胞欠乏症の治療処置
FR2807323A1 (fr) 2000-04-10 2001-10-12 Oreal Composition, notamment cosmetique, renfermant un steroide et un 2-alkyl alcanol ou un ester
CA2439687A1 (en) * 2001-03-01 2002-09-12 Hollis-Eden Pharmaceuticals, Inc. Use of certain steroids for treatment of blood cell deficiencies
CA2493605A1 (en) * 2001-07-25 2003-02-06 Richard A. Haase Processes and apparatus for the manufacture of polynuclear aluminum compounds and disinfectants, and polynuclear aluminum compounds and disinfectants from such processes and apparatus
FR2827765B1 (fr) * 2001-07-27 2003-09-19 Oreal Composition a base de vesicules lamellaires lipidiques incorporant au moins un compose a base de dhea
FR2827766A1 (fr) * 2001-07-27 2003-01-31 Oreal Composition a base de vesicules lamellaires lipidiques incorporant au moins un compose a base de dhea
US20040034003A1 (en) * 2002-05-01 2004-02-19 Schwartz Arthur G. 7-Hydroxy-16alpha-fluoro-5-androsten-17-ones and 7-hydroxy-16alpha-fluoro-5-androstan-17-ones and derivatives thereof
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US8268269B2 (en) 2006-01-24 2012-09-18 Clearvalue Technologies, Inc. Manufacture of water chemistries
US8273770B2 (en) 2007-07-21 2012-09-25 Albany Molecular Research, Inc. 5-pyridinone substituted indazoles
ES2558155T3 (es) 2007-10-30 2016-02-02 Indiana University Research And Technology Corporation Compuestos que muestran actividad antagonista de glucacón y agonista de GLP-1
JP2011504505A (ja) 2007-11-21 2011-02-10 デコード ジェネティクス イーエイチエフ 肺および心血管障害を治療するためのビアリールｐｄｅ４抑制剤
JP5501251B2 (ja) 2008-01-11 2014-05-21 アルバニー モレキュラー リサーチ， インコーポレイテッド Ｍｃｈ拮抗薬としての（１−アジノン）置換ピリドインドール類
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
PE20120332A1 (es) 2008-12-19 2012-04-14 Univ Indiana Res & Tech Corp Profarmacos de peptido de la superfamilia de glucagon basado en amida
BRPI1007350B8 (pt) 2009-01-26 2021-05-25 Israel Institute For Biological Res compostos espiro heterocíclicos bicíclicos
AU2010273732A1 (en) 2009-07-14 2012-02-09 Albany Molecular Research, Inc. 5-HT3 receptor modulators, methods of making, and use thereof
EP2569000B1 (en) 2010-05-13 2017-09-27 Indiana University Research and Technology Corporation Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
US9237762B2 (en) 2010-05-24 2016-01-19 Swedish Oat Fiber Ab Aqueous dispersion comprising galactolipids and method for production thereof
MX2012014576A (es) 2010-06-24 2013-02-21 Univ Indiana Res & Tech Corp Profarmacos de peptido de la superfamilia de glucagon basado en amida.
FR2979239A1 (fr) * 2011-08-25 2013-03-01 Trophos Liposome comprenant au moins un derive de cholesterol
US8859491B2 (en) 2011-11-17 2014-10-14 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
EP3768267A4 (en) 2018-03-20 2022-04-20 Icahn School of Medicine at Mount Sinai KINA INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE
CA3124700A1 (en) 2018-12-31 2020-07-09 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522803A (en) 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
US4588578A (en) 1983-08-08 1986-05-13 The Liposome Company, Inc. Lipid vesicles prepared in a monophase
US4518595A (en) 1983-07-19 1985-05-21 The Jackson Laboratory Method for treating diabetes using DHEA compounds
FR2551758B1 (fr) * 1983-08-16 1986-01-31 Anvar Derives de muramyl-peptides et de steroides ayant des proprietes d'activation des macrophages
US4666898A (en) 1983-12-28 1987-05-19 Jackson Lab. Treatment of obesity, diabetes and other symptoms of hypercorticoidism using etiocholanolones
US4507289A (en) 1983-12-28 1985-03-26 Progenics, Inc. Treatment of diabetes and other symptoms of hypercorticoidism using a synergistic combination of etiocholanolones and estrogen
US5231112A (en) 1984-04-12 1993-07-27 The Liposome Company, Inc. Compositions containing tris salt of cholesterol hemisuccinate and antifungal
CA1264668C (en) 1984-06-20 1990-01-23 EXTRUSION TECHNIQUES FOR THE PRODUCTION OF LIPOSOMES
EP0231261B1 (en) 1985-07-05 1994-04-06 The Liposome Company, Inc. Multilamellar liposomes having improved trapping efficiencies
US5041278A (en) 1985-10-15 1991-08-20 The Liposome Company, Inc. Alpha tocopherol-based vesicles
US4861580A (en) 1985-10-15 1989-08-29 The Liposome Company, Inc. Composition using salt form of organic acid derivative of alpha-tocopheral
DE3626421A1 (de) * 1986-08-05 1988-02-11 Recipe Pharma Vertriebs Gmbh & Peptid, pharmazeutisches mittel und verwendung desselben zur stimulierung der lipolyse
US5006517A (en) 1987-12-01 1991-04-09 Progenics, Inc. Treatment of Prader-Willi syndrome
US5041287A (en) 1989-05-22 1991-08-20 Terry L. Driggers Sprayable composition using acetone solvent
US5126324A (en) 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
AU668934B2 (en) 1992-04-10 1996-05-23 Hisamitsu Pharmaceutical Co., Inc. Liposome composition
WO1994004155A1 (en) * 1992-08-19 1994-03-03 Health Resource Institute, Ltd. Dehydroepiandrosterone therapy for the treatment of eye disorders
US6015576A (en) * 1997-08-29 2000-01-18 Bio-Sphere Technology, Inc. Method for inducing a systemic immune response to an antigen

Also Published As

Publication number Publication date
EP0801557B1 (en) 2003-07-02
DE69628909D1 (de) 2003-08-07
IL121070A (en) 2004-06-20
CA2208215A1 (en) 1997-04-17
JPH10508322A (ja) 1998-08-18
WO1997013500A3 (en) 1997-05-29
ATE243998T1 (de) 2003-07-15
EP0801557A2 (en) 1997-10-22
HUP9801834A2 (hu) 1999-02-01
DE69628909T2 (de) 2003-12-24
WO1997013500A2 (en) 1997-04-17
CN1173815A (zh) 1998-02-18
US6436435B1 (en) 2002-08-20
IL121070A0 (en) 1997-11-20

Similar Documents

Publication Publication Date Title
HUP9801834A3 (en) Liposome formulations of 5beta steroids
EP0863748A4 (en) LIPOSOMAL COMPOSITIONS AND METHODS OF USE
AU5557796A (en) Liposome drug-loading method and composition
EP0840737A4 (en) TRITERPENES
IL119649A0 (en) Preparation of steroid derivative ketal
IL116924A (en) Preparation of n-aryl - and n-hetarylhydroxylamines
IL117668A0 (en) Preparation of polyesters
IL119818A (en) Microbial 11alpha-hydroxylation of steroids
AU5315096A (en) 19-oxygenated steroids as therapeutic agents
ZA968873B (en) Isomerisation of equillin
IL117786A (en) Preparation of alpha-bisoximes
GB2305006B (en) Manufacture of switchgear
NZ307236A (en) Preparation of streptogramins
GB9606017D0 (en) Manufacture of steroids
ZA985088B (en) Processes for preparation of 9,11-epoxy steroids and intermediates useful therein
AU7574996A (en) Liposomal transfection method
GB9520976D0 (en) Preparation of liposomes
IL158857A0 (en) Processes for preparation of steroids and intermediate useful therein
GB9514072D0 (en) Preparation of thionucleosides
IL115554A0 (en) Earthquake-proofing of structures
TW307343U (en) Improved structure of chair
TW320878U (en) Improved structure of hairpin
HU9503668D0 (en) Attaching means of hooses
AU2003200612A1 (en) Liposomal compositions and methods of using them
TW302940U (en) Structure of handrail